Baycol
Baycol, also known as Cerivastatin Sodium, was approved for use in 1997. It is a popular cholesterol-lowering drug and is prescribed to control the excess cholesterol in the bloodstream that leads to hardening of the arteries and heart disease. Approximately 700,000 Americans were prescribed with the drug. Baycol was intended to lower both total cholesterol and LDL ("bad") cholesterol, while raising the HDL ("good") cholesterol that clears the arteries. Patients taking...MORE >>
Links and Resources
Featured Articles on Baycol
- July 2004 - Baycol Lawsuits; New Baycol Cases
- April 2004 - Minnesota Court Orders Supplemental Discovery in Baycol Litigation
- May 8, 2003 - Baycol Settlements on the Rise
- March 18, 2003 - Bayer Victorious in First Baycol Trial
- February 18, 2003 - First Baycol Trial Begins in Texas
- August 12, 2002 - Bayer CEO Ready to Settle Baycol Lawsuits in Individual Cases
- Sep 06, 2001 - Firm announces class action lawsuit against Bayer
- Aug 17, 2001 - Bayer facing mounting US lawsuits over anti-cholesterol drug
- Aug 08, 2001 - Bayer voluntarily recalls Baycol
- May 21, 2001 - Letter: Prescribing Information changes to reduce risk of myopathy and rhadomyolysis
Browse Books About Drug Litigation 
1.The Drug Lords : America's... 
2.Deadly Drug Interactions : The People's... 
3.The Pdr Family Guide to Prescription... 
4.The Essential Guide to Prescription... 
5.2001 Mosby's GenRx: A Comprehensive... 
6.The American Pharmaceutical... 
The personal injury information offered by Pasadena, California personal injury Lawyer and contained herein, regarding Pasadena, California personal injury statutes and Pasadena, California personal injury claimants' rights, is general in scope. No Pasadena, California personal injury attorney / client relationship with our Pasadena, California personal injury attorneys is hereby formed nor is the information herein intended as formal legal advice. Please contact a Pasadena, California personal injury lawyer regarding your specific inquiry. See Terms of Use.